��������

Ofer Gonen joined MediWound’s leadership team as Chief Executive Officer in July 2022, bringing more than 20 years of experience in managing global life science companies. Prior to his CEO appointment, Mr. Gonen served as CEO of Clal Biotechnology Industries Ltd. (TASE: CBI), Israel’s leading life science investment company, as well as a managing partner at the Anatomy Medical Technologies Fund. Mr. Gonen served as the General Manager of Biomedical Investments Ltd., a managing partner at Arte Venture Group, and held a variety of executive positions in the industry. In addition, Mr. Gonen founded Cactus Acquisition Corp. 1 (Nasdaq: CCTS), focused on healthcare companies. Mr. Gonen held board member positions at several private and publicly traded companies, including Gamida Cell (Nasdaq: GMDA), Cactus (Nasdaq: CCTS), Anchiano Therapeutics (Nasdaq: ANCN), MediWound (Nasdaq: MDWD), Polyheal, Elicio Therapeutics, and eXIthera Pharmaceuticals. Mr. Gonen received a B.Sc. in Physics, Mathematics, and Chemistry from the Hebrew University of Jerusalem, and an M.A. in Economics and Finance from Tel Aviv University, with distinction. He graduated from the prestigious “Talpiot” program of the Israeli Defense Forces.